BRAF and melanoma: For instance, in BRAF mutant melanoma, in which targeted inhibitors are known to be at their highest performance, immune checkpoint inhibitors showed a 20% benefit over targeted compounds in terms of overall survival among therapy-naïve and metastatic patients51.